TY - JOUR
T1 - Microsphere-based drug releasing scaffolds for inducing osteogenesis of human mesenchymal stem cells in vitro
AU - Shi, Xuetao
AU - Wang, Yingjun
AU - Varshney, Rohan R.
AU - Ren, Li
AU - Gong, Yihong
AU - Wang, Dong An
N1 - Funding Information:
Shi Xuetao is a China Scholarship Council (CSC) scholarship recipient ( 2007U33046 ). This research was supported by National Natural Science Foundation of China (Grant 50572029 ), the Key Programs of the Ministry of Education (Grant 305012 ), the State Key Program of National Natural Science of China (Grant 50732003 ). The research was also supported by AcRF Tier 1 RG 64/08, Ministry of Education, Singapore.
PY - 2010/1/31
Y1 - 2010/1/31
N2 - In this study, in vitro osteogenesis was successfully achieved in human mesenchymal stem cells (hMSCs) by controlled release of the osteogenesis-inducing drugs dexamethasone, ascorbic acid (AA) and β-glycerophosphate (GP) from poly(lactic-co-glycolic acid) (PLGA) sintered microsphere scaffolds (SMS). We investigated the osteogenesis of human MSCs (hMSCs) on dexamethasone laden PLGA-SMS (PLGA-Dex-SMS), and dexamethasone, AA and GP laden PLGA-SMS (PLGA-Com-SMS). hMSCs cultured on the microsphere systems, which act as drug release vehicles and also promote cell growth/tissue formation-displayed a strong osteogenic commitment locally. The osteogenic commitment of hMSCs on the scaffolds were verified by alkaline phosphatase (ALP) activity assay, calcium secretion assay, real-time PCR and immunohistochemistry analysis. The results indicated hMSCs cultured on PLGA-Com-SMS exhibited superior osteogenic differentiation owing to significantly high phenotypic expression of typical osteogenic genes-osteocalcin (OC), type I collagen, alkaline phosphatase (ALP), and Runx-2/Cbfa-1, and protein secretion of bone-relevant markers such as osteoclast and type I collagen when compared with PLGA-Dex-SMS. In conclusion, by promoting osteogenic development of hMSCs in vitro, this newly designed controlled release system opens a new door to bone reparation and regeneration.
AB - In this study, in vitro osteogenesis was successfully achieved in human mesenchymal stem cells (hMSCs) by controlled release of the osteogenesis-inducing drugs dexamethasone, ascorbic acid (AA) and β-glycerophosphate (GP) from poly(lactic-co-glycolic acid) (PLGA) sintered microsphere scaffolds (SMS). We investigated the osteogenesis of human MSCs (hMSCs) on dexamethasone laden PLGA-SMS (PLGA-Dex-SMS), and dexamethasone, AA and GP laden PLGA-SMS (PLGA-Com-SMS). hMSCs cultured on the microsphere systems, which act as drug release vehicles and also promote cell growth/tissue formation-displayed a strong osteogenic commitment locally. The osteogenic commitment of hMSCs on the scaffolds were verified by alkaline phosphatase (ALP) activity assay, calcium secretion assay, real-time PCR and immunohistochemistry analysis. The results indicated hMSCs cultured on PLGA-Com-SMS exhibited superior osteogenic differentiation owing to significantly high phenotypic expression of typical osteogenic genes-osteocalcin (OC), type I collagen, alkaline phosphatase (ALP), and Runx-2/Cbfa-1, and protein secretion of bone-relevant markers such as osteoclast and type I collagen when compared with PLGA-Dex-SMS. In conclusion, by promoting osteogenic development of hMSCs in vitro, this newly designed controlled release system opens a new door to bone reparation and regeneration.
KW - Ascorbic acid
KW - Dexamethasone
KW - Mesenchymal stem cell
KW - Osteogenesis
KW - Poly(lactic-co-glycolic acid)
KW - β-Glycerophosphate
UR - http://www.scopus.com/inward/record.url?scp=73749083416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73749083416&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2009.10.012
DO - 10.1016/j.ejps.2009.10.012
M3 - Article
C2 - 19895885
AN - SCOPUS:73749083416
VL - 39
SP - 59
EP - 67
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
SN - 0928-0987
IS - 1-3
ER -